Clinical Trials Logo

ROS1 Gene Rearrangement clinical trials

View clinical trials related to ROS1 Gene Rearrangement.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04989322 Recruiting - Nsclc Clinical Trials

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Start date: October 5, 2021
Phase: Phase 2
Study type: Interventional

Adding chemotherapy or anti-VEGF to immunotherapy is an emerging strategy to enhance the efficacy of immunotherapy in many cancers. This phase 2 study aims to explore the preliminary efficacy of combination pembrolizumab with lenvatinib and chemotherapy in NSCLC patients with sensitizing EGFR, ALK, or ROS1 genetic aberration refractory to standard targeted therapy.

NCT ID: NCT04084717 Recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Start date: December 3, 2019
Phase: Phase 2
Study type: Interventional

This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at treating ROS1 or MET mutated non-small cell lung cancer. Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.

NCT ID: NCT03608007 Recruiting - Lung Cancer Clinical Trials

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

Start date: June 15, 2018
Phase: Phase 2
Study type: Interventional

To assess treatment effectiveness and safety of oral X-396 capsule (Ensartinib) administered to Chinese patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a c-ROS Oncogene (ROS1) positive gene mutation (translocation or inversion).